SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems VS-7375 clinical update is the main focus, with the company reporting encouraging KRAS G12D activity, including a 50% confirmed response rate in second-line pancreatic cancer, alongside favorable tolerability. Traders are weighing the results potential against the stocks decline and a newly priced share offering; some view the offering price as investor confidence, while others are concerned about dilution.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Discussion centers on new immune-biomarker findings for Candels CAN-2409 prostate cancer program and the planned BLA submission, with bullish traders viewing the data as support for the treatments potential and regulatory case. Others remain concerned about the stocks decline despite positive updates, BLA timing, and possible dilution, with some also criticizing the CEOs share sale.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias settlement with United Therapeutics resolves their litigation and keeps YUTREPIA available for PAH, while the PH-ILD indication is being removed. Traders see relief from the risk of losing access to the market, but debate whether the costly settlement and lost indication outweigh that benefit.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

Skydances distribution of long-dated warrants and the shift to ex-warrant trading dominate discussion, with traders debating whether the share-price adjustment reflects the warrants separated value or additional selling pressure. Concerns about potential dilution and the debt burden from the Warner Bros. Discovery deal add to the bearish reaction, while some holders argue the warrants offset the stocks decline.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid a broader AI-infrastructure selloff, as OpenAI revenue disclosures renewed doubts about whether AI demand can support the sectors heavy buildout. Bears are also focused on CoreWeaves debt, capital spending and financing costs, while bulls call the demand concerns overblown and point to its backlog and capacity expansion.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASMLs quarterly results and raised full-year sales outlook are driving discussion, with management citing strong AI-related equipment demand that may outstrip planned supply in coming years. Traders are divided over the share-price decline: bulls call it a sell-the-news reaction to solid results and demand, while skeptics point to a slight sales miss and the lack of a 2027 outlook.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics global settlement with Liquidia resolves six lawsuits and keeps YUTREPIA available for PAH while removing its PH-ILD indication, a development traders view as protecting UTHRs Tyvaso franchise. Some posts note that Liquidias continued PAH sales limit the competitive impact, while others question why UTHR shares have reacted modestly to the deal.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

CEO Ryan Cohens latest large open-market share purchase, continuing a run of insider buying, is driving attention. Many traders view it as a bullish signal and link it to warrant-related or short-squeeze speculation, while others argue insider purchases alone are not a substitute for meaningful company news.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas $2 billion strategic investment in Summit Therapeutics, paired with plans to study Summits cancer drug ivonescimab in combination with AstraZeneca therapies, is drawing attention. Traders largely describe the deal as a vote of confidence and an expansion of AZNs oncology strategy, while some question Summits valuation and stress that the investment is not a buyout.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Googles Gemini 4 Argon rollout is driving AI-focused discussion, with traders debating its competitiveness against Meta and other frontier models. Reactions are mixed: some expect the launch and cloud growth to support the shares, while others point to a muted, choppy price response and fading hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire TAMPA, Fla., June 2, 2026 Issued on behalf of Conexeu Sciences Inc.A newly listed...

Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-organogenesis-holdings-inc-stock...

Organogenesis (NASDAQ:ORGO) Trading Up 1.7% - Time to Buy?

Organogenesis (NASDAQ:ORGO) Shares Up 1.7% - What's Next...

ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment 

Equity

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.


Organogenesis (NASDAQ:ORGO) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 price objective on shares of Organogenesis in a research report on Thursday...

Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO

Assenagon Asset Management S.A. raised its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities...

Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC

First Light Asset Management LLC lifted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys 5,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $2.68...

Michael Joseph Driscoll Buys 10,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll purchased 10,000 shares of the business's stock in a transaction on Monday, March 9th. The shares were purchased at an...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz acquired 5,000 shares of the firm's stock in a transaction on Monday, March 9th. The shares were acquired at an average price...

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis Holdings Inc - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.21
Prev Close	$1.23
Open	$1.24
Dividend Yield	0.00%
50-Day Moving Average	$1.61
Beta	1.82
Avg. Volume	657,753.27
PE Ratio	-1.45

52-Week High	$7.08
52-Week Low	$1.20
Market Capitalization	$158.27M
EPS (Annual)	$0.1537
Price to Book	1.05
Revenue Per Employee	$660,619.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORGO Fundamentals